ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to develop their lead vaccine. The signing of the agreement is yet another milestone in a series of fruitful collaborations between Nobelpharma and ProBioGen, among them the successful development of a highly efficient manufacturing process for Nobelpharma's highly relevant viral vaccine.

The advantages of ProBioGen's proven cell-based production platform for industrial processes are evident: Designed as a true suspension cell line, the AGE1.CR.pIX grows in a chemically defined medium and is free of any adventitious agents. This allows cultivation in large bioreactors with reduced lead times and thus a more controlled production process in closed systems.

Dr Gabriele Schneider, Chief Business Officer at ProBioGen commented: "Cell-based systems for vaccine production offer a cost-effective, efficient and flexible alternative to traditional vaccine production, e. g. on chicken eggs. With the AGE1.CR.pIX, we have created an exceptionally robust and scalable system, which is becoming increasingly important and we are pleased about the increased demand."